Table 1.
Characteristics of subjects.
Table 2.
Bilirubin and liver enzymes le0076els in subgroups of AIP and PAC.
Fig 1.
Comparison of serological parameters in patients with autoimmune pancreatitis (AIP) and pancreatic adenocarcinoma (PAC).
In all the panels, each circle represents a measurement for one patient. Levels of each parameter are expressed as median (horizontal bar in the middle) and interquartile range (within 75th percentile and 25th percentile bars from upper to lower). P values are obtained from Mann–Whitney U test. AIP autoimmune pancreatitis, PAC pancreatic adenocarcinoma. AIP(M) autoimmune pancreatitis in male patients, AIP(F) autoimmune pancreatitis in female patients, PAC(M) pancreatic adenocarcinoma in male patients, PAC(F) pancreatic adenocarcinoma in female patients.
Table 3.
Elevation or decease frequency of serum markers.
Fig 2.
Receiver operating curve of A. Ca 19–9, B. Eosinophil percentage, C. Globulin level, D. Hemoglobin (male), E. Hemoglobin (female) and F. Combined four serological markers.
Table 4.
Diagnostic performance of serological parameters singly and combined, to differentiate AIP and PAC.
Table 5.
Results of the logistic regression analysis for AIP.
Fig 3.
An algorithm of clinical pathway for distinguishing autoimmune pancreatitis from pancreatic cancer.
Strategy for initiation of AIP wok-up is based on combined analysis of Ca19-9 level, Eosinophil percentage, Globulin and Hemoglobin level. Elevated eosinophil percentage, globulin level together with decreased hemoglobin level are suggestive of AIP. According to our present study, Ca19-9 < 306.75 u/ml, E%>4.15%, Globulin>29.80 g/L and Hb (M) < 114.5 g/L Or Hb (F) < 118.5 g/L are suggested to be the cut-off value for diagnosis. Abbreviations: AIP, autoimmune pancreatitis; ICDC, International Consensus Diagnostic Criteria for AIP; HISORt, histology, imaging, serology, other organ involvement, response to steroid therapy criteria for autoimmune pancreatitis.